文献速递糖尿病肥胖与代谢综合征

重新审视「好胆固醇」:临床医生理解HDL的指南

Rethinking good cholesterol: a clinicians' guide to understanding HDL.
PubMed 文献 · Lancet Diabetes Endocrinol · 2019-03-22

低HDL胆固醇血症影响约半数2型糖尿病患者,是动脉粥样硬化性心血管疾病的独立危险因素。本文回顾HDL假说历史,指出悖论源于将HDL与HDL胆固醇错误混淆,并讨论HDL新功能及对2型糖尿病的意义。

要点

  • 低HDL胆固醇血症影响约半数2型糖尿病患者,是动脉粥样硬化性心血管疾病的独立危险因素。
  • HDL胆固醇升高药物的阴性结果挑战了「好胆固醇」标签,悖论源于混淆HDL与HDL胆固醇。
  • HDL胆固醇作为一级心血管疾病风险预测模型组分仍有价值,但应弃用「好胆固醇」标签。

核心结论

  • HDL胆固醇是复杂多功能脂质转运系统的不完美生物标志物,应弃用「好胆固醇」标签以避免预后过度泛化。

主要发现

  • 低HDL胆固醇血症影响约半数2型糖尿病患者,是动脉粥样硬化性心血管疾病的独立危险因素。
  • HDL胆固醇升高药物的阴性结果挑战了HDL胆固醇在动脉粥样硬化性心血管疾病中因果作用的假设。
  • 悖论根源于对HDL与HDL胆固醇区别的逐步错误模糊。
  • HDL颗粒组成复杂,除胆固醇载货外还具有脂质转运及影响糖代谢等新功能。

临床怎么用

  • 在缺乏更优替代指标时,HDL胆固醇通常可作为一级心血管疾病风险预测模型的组分,包括2型糖尿病患者。
  • 临床应避免将HDL胆固醇简单视为「好胆固醇」而过度泛化预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low HDL cholesterol dyslipidaemia affects about half of people with type 2 diabetes and represents a major independent risk factor for atherosclerotic cardiovascular disease. The "good cholesterol" label was coined decades ago on the basis of a presumed causal role of HDL cholesterol in atherosclerotic cardiovascular disease. However, this view has been challenged by the negative results of several studies of HDL cholesterol-raising drugs, creating a paradox for clinicians regarding the value of HDL cholesterol as a risk biomarker and therapeutic target, and seemingly contradicting decades of evidence substantiating an inverse relation between HDL cholesterol and cardiovascular disease risk. We seek to resolve this issue by revisiting the history of the HDL hypothesis, chronicling how this paradox is ultimately rooted in the progressive erroneous blurring of the distinction between HDL and HDL cholesterol. We describe the compositional complexity of HDL particles beyond their cholesterol cargo and focus on their role in lipid transport. We discuss the evidence regarding novel HDL functions, including effects on glucose metabolism, and speculate on the implications for type 2 diabetes. HDL cholesterol is an imperfect biomarker of a highly complex and multifunctional lipid transport system, and we should now consider how new HDL markers more causally linked to cardiovascular complications could be adapted for clinical use. In the absence of a superior alternative, HDL cholesterol generally has value as a component of primary cardiovascular disease risk prediction models, including in people with type 2 diabetes. However, to avoid prognostic overgeneralisations, it is high time that the good cholesterol label is dropped.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Xiang AS, Kingwell BA. Rethinking good cholesterol: a clinicians' guide to understanding HDL. Lancet Diabetes Endocrinol. 2019. PMID: 30910502. doi:10.1016/S2213-8587(19)30003-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。